Researchers race against extinction to uncover tree's cancer-fighting properties

January 17, 2019, Purdue University
A Chinese stamp honoring the critically endangered tree was issued in 1992. Credit: Designed by Zeng Xiaolian

Three Chinese fir trees on a nature reserve in Southeastern China are the last of their kind. As their existence is threatened by human disturbance and climate change, researchers are hurrying to learn everything they can about the tree—which might inspire new and more effective ways to treat various cancers.

Chemists in China were initially studying the tree, Abies beshanzuensis, to look for molecules that might be able to treat diabetes and obesity. Using only bark and needles that fell from the trees, in order to not further disturb the small population, researchers found that the tree's makeup wasn't as effective as they'd hoped in treating these diseases.

The tree's healing powers looked grim until Mingji Dai, an organic chemist at Purdue University, started tinkering with some of its molecules in his lab. His team created synthetic versions of two, and then a few analogs, which have minor structural modifications. In collaboration with Zhong-Yin Zhang, a distinguished professor of medicinal chemistry at Purdue, he found that one of the synthetic analogs was a potent and selective inhibitor of SHP2, an increasingly popular target for treatment. The findings were published in the Journal of the American Chemical Society.

"This is one of the most important anti-cancer targets in the pharmaceutical industry right now, for a wide variety of tumors," Dai said. "A lot of companies are trying to develop drugs that work against SHP2."

Cancer was projected to take more than 600,000 lives in the United States alone in 2018, according to the National Cancer Institute. Targeted therapies help treat cancer by interfering with specific proteins that help tumors grow and spread throughout the body. Unlike many of the molecules used to target SHP2 right now, Dai's (referred to as "compound 30") forms a with the SHP2 protein.

"With others, it's a looser binding. Ours forms a covalent bond, which is more secure and long-lasting," Dai said. "But we also wondered whether this type of molecule could interact with other proteins."

With help from chemical biologists at the Scripps Research Institute in Florida, the team went fishing—in a pond full of proteins. Using a tagged version of compound 29 (which is just a bit structurally different from compound 30) as bait, they caught POLE3, an enzyme that helps synthesize and repair DNA molecules.

This told the team that POLE3 and compound 29 were interacting, but not much else. Alone, compound 29 had no effect on cancer cells. But they knew this compound was drawn to a target protein involved in DNA synthesis, so they started looking for FDA-approved cancer drugs that target DNA for potential combination therapy. They found Etoposide, a DNA-damaging drug used to treat multiple types of cancer. Together, the results were promising.

"Compound 29 alone doesn't kill cancer, but when you combine it with Etoposide, the drug is much more effective," Dai said. "This could improve some of the cancer drugs used today, and it also tells us something new about the function of POLE3. People weren't targeting this for before, but our findings offer a new strategy for killing cancer cells."

Explore further: New drugs could also be deployed against lung and pancreatic cancers

More information: Dexter C. Davis et al, Total Synthesis, Biological Evaluation, and Target Identification of Rare Abies Sesquiterpenoids, Journal of the American Chemical Society (2018). DOI: 10.1021/jacs.8b07652

Related Stories

VCP protein inhibitor found to help virus kill liver tumors

August 24, 2017

(Medical Xpress)—A team of researchers with members from several institutions in China has found that combining a VCP protein inhibitor with a virus that naturally targets liver cancer tumors made the virus much more potent. ...

Breakthrough for difficult-to-treat breast cancer

August 29, 2018

Chemists at Hong Kong Baptist University (HKBU) have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most difficult forms of breast ...

Recommended for you

Multiple stellar populations detected in the cluster Hodge 6

February 18, 2019

Using ESO's Very Large Telescope (VLT), astronomers have found that the cluster Hodge 6 hosts multiple stellar populations. The detection could provide important hints on the formation and evolution of Hodge 6 and star clusters ...

Predicting sequence from structure

February 18, 2019

One way to probe intricate biological systems is to block their components from interacting and see what happens. This method allows researchers to better understand cellular processes and functions, augmenting everyday laboratory ...

Energetic particles can bombard exoplanets

February 18, 2019

TRAPPIST-1 is a system of seven Earth-sized worlds orbiting an ultra-cool dwarf star about 120 light-years away. The star, and hence its system of planets, is thought to be between five-to-ten billion years old, up to twice ...

Meteorite source in asteroid belt not a single debris field

February 17, 2019

A new study published online in Meteoritics and Planetary Science finds that our most common meteorites, those known as L chondrites, come from at least two different debris fields in the asteroid belt. The belt contains ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Jan 18, 2019
Better hurry. you never know when the tropical rain forest will turn to Tundra or Prairie.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.